Baird Maintains an 'Outperform' on Vertex (VRTX); Latest HCV Survey Suggests Incivek Launch Should Remain a Positive Story

Baird maintains an 'Outperform' on Vertex (NASDAQ: VRTX).

Baird analyst says, "Remain Outperform-rated on survey data confirming positive launch trends for Incivek (telaprevir). This is confirmatory of bullish trends reported by VRTX and additive to perspectives previously gleaned from key opinion leaders driving much early prescribing. Feedback was positive on market growth, projected share trends and perceptions of new protease inhibitors, and first impressions of the sales/marketing efforts. VRTX still has its work cut out on sustainability, but we expect launch to remain a positive story the rest of this year."

For more ratings news on Vertex click here and for the rating history of Vertex click here.

Shares of Vertex closed at $44.45 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• RBC Capital on Vertex (VRTX): 'SION Overhang Cleared; We Would Remain Buyers'
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Vertex (VRTX) PT Raised to $562 at Wolfe Research